Grassley seeks Zyprexa documents
Executive Summary
Senator Chuck Grassley, R-Iowa, is requesting that Lilly produce documents related to liability cases regarding Zyprexa (olanzapine). The Finance Committee Ranking Member sent an April 4 letter asking for documents that were made available to plaintiffs in various lawsuits alleging Lilly inadequately warned patients of risks associated with the atypical antipsychotic. The company recently announced it will pay up to $500 million to settle 18,000 claims, leaving 1,200 claims outstanding (1"The Pink Sheet" Jan. 8, 2007, p. 16)...
You may also be interested in...
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.